China’s homegrown flu pipeline grows as Zhongsheng’s onradivir wins Phase III nod for high-risk patients
New treatments are expanding beyond conventional flu therapy into high-risk patients and prevention, as Chinese drugmakers…
Latest
- China’s homegrown flu pipeline grows as Zhongsheng’s onradivir wins Phase III nod for high-risk patients
- China to issue digital IDs for EV batteries
- Kuaishou spinoff Transtreams Technology raises 1 billion yuan to fund AI video chip development
- SinoHytec turns to energy storage for growth as hydrogen vehicle market shrinks
- How ByteDance turned China’s AI micro-drama craze into a cash machine — and a regulatory headache
